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Abstract
Background: The manufacture of mesenchymal stem/stromal cells (MSCs) for clinical use needs to be cost effective,
safe and scaled up. Current methods of expansion on tissue culture plastic are labour-intensive and involve several
‘open’ procedures. We have used the closed Quantum® hollow fibre bioreactor to expand four cultures each of MSCs
derived from bone marrow (BM) and, for the first time, umbilical cords (UCs) and assessed extensive characterisation
profiles for each, compared to parallel cultures grown on tissue culture plastic.
Methods: Bone marrow aspirate was directly loaded into the Quantum®, and cells were harvested and characterised at
passage (P) 0. Bone marrow cells were re-seeded into the Quantum®, harvested and further characterised at P1. UC-MSCs
were isolated enzymatically and cultured once on tissue culture plastic, before loading cells into the Quantum®,
harvesting and characterising at P1. Quantum®-derived cultures were phenotyped in terms of immunoprofile, tri-lineage
differentiation, response to inflammatory stimulus and telomere length, as were parallel cultures expanded on tissue
culture plastic.
Results: Bone marrow cell harvests from the Quantum® were 23.1 ± 16.2 × 106 in 14 ± 2 days (P0) and 131 ± 84 × 106
BM-MSCs in 13 ± 1 days (P1), whereas UC-MSC harvests from the Quantum® were 168 ± 52 × 106 UC-MSCs after 7 ± 2
days (P1). Quantum®- and tissue culture plastic-expanded cultures at P1 adhered to criteria for MSCs in terms of cell
surface markers, multipotency and plastic adherence, whereas the integrins, CD29, CD49c and CD51/61, were found to
be elevated on Quantum®-expanded BM-MSCs. Rapid culture expansion in the Quantum® did not cause shortened
telomeres when compared to cultures on tissue culture plastic. Immunomodulatory gene expression was variable
between donors but showed that all MSCs upregulated indoleamine 2, 3-dioxygenase (IDO).
Conclusions: The results presented here demonstrate that the Quantum® can be used to expand large numbers of
MSCs from bone marrow and umbilical cord tissues for next-generation large-scale manufacturing, without impacting
on many of the properties that are characteristic of MSCs or potentially therapeutic. Using the Quantum®, we
can obtain multiple MSC doses from a single manufacturing run to treat many patients. Together, our findings
support the development of cheaper cell-based treatments.
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Introduction
Bone marrow-derived mesenchymal stem/stromal cells
(BM-MSCs) were first described in 1968 [1] and were
suggested to have multilineage potential in 1991 [2].
Since then, there has been huge interest in investigating
the potential of these cells in the development of
cell-based therapies. BM-MSCs have been shown to
differentiate into bone, cartilage and fat lineages in vitro
[3] and have been used clinically in orthopaedics and in
other fields, most notably in the treatment of graft
versus host disease (GvHD). Numerous tissue sources
for the derivation of MSCs have been identified, inclu-
ding umbilical cord and adipose tissues [4, 5].
The minimal criteria for MSC characterisation were
first published in 2006 by the International Society for
Cellular Therapy (ISCT) [6], which were subsequently
amended for adipose-derived MSCs [7]. In recent years,
there has been an increasing body of evidence from in
vitro and in vivo studies suggesting that MSCs exert
their therapeutic potency via trophic effects on endogen-
ous cells as well as by the secretion of immunomodula-
tory molecules [8–12]. Further, it is well established that
the ability of MSCs to modulate inflammatory processes is
enhanced by their stimulation with pro-inflammatory cy-
tokines (present in many disease states), such as tumour
necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and
interferon-γ (IFN-γ) [9, 13]. A more recent statement
paper was published by the ISCT in 2013 [9], which
included detailed criteria for the immunomodulatory
characteristics of MSCs. This working proposal advises
that the characterisation of stem cells for therapy should
include activation or ‘licencing’, which involves MSC
culture stimulation with IFN-γ, either alone or with the
addition of TNF-α [9].
MSCs derived from bone marrow and, more recently,
umbilical cords (UC-MSCs) have been receiving increas-
ing interest in the field of clinical orthopaedic regenera-
tive medicine [14–17]. We have previously studied these
MSC types separately and have compared the phe-
notypes of these cells in in vitro studies [5]. We are
currently assessing BM-MSCs versus UC-MSCs in pre-
clinical in vivo cartilage injury and osteoarthritis models.
Autologous culture-expanded BM-MSCs are also being
assessed in a randomised clinical trial for cartilage repair,
comparing their efficacy versus the current cell therapy
‘gold standard’, autologous chondrocyte implantation
(ACI), alone or in combination in the ASCOT trial [18].
BM-MSCs have been used clinically both in autologous
[19] and in allogeneic transplantations [20, 21], whereas
UC-MSC therapies are being developed as an allogeneic
treatment option [22]. Allogeneic cell therapies have
many obvious advantages over autologous options as
they can be developed as an ‘off-the-shelf ’ therapy with
one-step treatment and the ability to bank several doses
from a single production run, thereby significantly
reducing both manufacturing and treatment costs.
Moreover, allogeneic cell therapies can be employed when
autologous options are not suitable, for instance when
autologous donor tissues such as bone marrow might not
yield a biologically relevant cell mass, which is likely the
case for extremely elderly orthopaedic patients.
There are several publications describing the best
practice for the expansion and of the UC-MSC popula-
tions using traditional TCP techniques and for the cryo-
genic banking of UC-MSCs for allogeneic clinical use
[23–25]. The good manufacturing practice (GMP) com-
pliant Quantum® bioreactor, manufactured by Terumo
BCT, has been used in several pre-clinical and clinical
production runs for BM-MSCs and MSCs derived from
adipose tissues [26–36], but to our knowledge has not
been used to expand UC-MSCs. Sub-populations of cells
(distinct in morphology to MSCs) have been described
following the initial expansion phase of cells from the
bone marrow [37], but these are poorly characterised.
The bioreactor itself is made up of ~ 11.5 × 103 polysul-
phone hollow fibres with semi-permeable membranes,
which equates to a surface area of 2 .1 m2. Each fibre is
approximately 215 μm in diameter and as such is only
suitable for thin surface coatings and monolayers of
adherent cells, rather than cell clusters and tissues.
Monolayer cultures are monitored for growth by analys-
ing media taken from a sample port to measure glucose
and lactate concentrations, since these small molecules
pass freely across the bioreactor membranes. The system
has been shown to effectively scale-up MSC manufac-
turing, required for the switch from autologous to allo-
geneic manufacture and multi-dose banking [28, 31].
The proliferative capacity of MSCs at low passage may be
critical to forming useful cell banks since there are reports
that BM-MSC at higher passage number (passage 5 to 10)
may have diminished efficiency and reduced therapeutic
effect in vivo [38]; however, no studies to our knowledge
have assessed Quantum® products in terms of their
longevity at low passage.
In the current study, we have assessed the Quantum®
system for the isolation and expansion of BM-MSCs dir-
ectly from bone marrow aspirate and have re-seeded
BM-MSCs into the system for a two-phase Quantum®
expansion. We have uniquely and comprehensively char-
acterised BM-MSCs and their sub-populations at both
expansion phases. In addition, for the first time to our
knowledge, we have assessed the Quantum® bioreactor
for the up-scale manufacture of UC-MSC using a
‘hybrid’ process, whereby UC-MSCs have been isolated
from tissues onto tissue culture plastic (TCP), as
described previously [5, 39], and have been re-seeded into
the Quantum® for the second expansion phase. We have
aimed to comprehensively characterise the Quantum®
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BM- and UC-MSC products compared to TCP parallel
populations, according to the ISCT criteria for MSCs and
using a panel of markers indicative of chondrogenic po-
tency, immunomodulatory capacity, and have assessed
their longevity in terms of telomere length.
Materials and methods
The overall experimental design is illustrated in
Additional file 1 to add clarity.
BM-MSC isolation and expansion
Four BM aspirates were obtained from Lonza (Walkers-
ville, Maryland, WV), sourced from healthy male donors
aged 22–32 years, with informed consent. Twenty millili-
tres of BM was initially loaded into the Quantum® at pas-
sage (P) 0. Quantum® expansion methodologies are
described in a subsequent section. A parallel culture
at P0 was grown on tissue culture TCP for compari-
son. For TCP cultures, 5 ml of BM was diluted 1:1
with Dulbecco’s phosphate-buffered saline (PBS; Life
Technologies, Paisley, UK) and was carefully layered
over Lymphoprep (Fresenius Kabi Norge, Norway).
Mononuclear cells were isolated after being centrifuged at
900g for 20min, re-suspended in complete medium (con-
taining Dulbecco’s modified Eagle’s medium (DMEM-F12)
containing 10% foetal calf serum (FCS; Life Technologies)
and 1% penicillin/streptomycin (P/S; Life Technologies))
and centrifuged again at 750g for 10 min. The resulting
pellet was plated out in a complete medium at a seeding
density of 20 × 106 cells per 75-cm2 flask. After 24 h,
non-adherent cells were removed by changing the
medium and adherent cells were cultured in monolayer. A
second expansion in the Quantum® (P1) was undertaken
after re-seeding the bioreactor with 5–10 × 106 BM-MSCs.
Again, a parallel culture of BM-MSCs was grown on
TCP for comparison. TCP medium was changed every
2–3 days. All cells were maintained in a humidified at-
mosphere at 5% CO2 and 21% O2 at 37 °C until they
reached 70–80% confluence at which time cultures
were passaged by trypsinisation.
UC-MSC isolation and expansion
Umbilical cords were collected with informed maternal
consent and processed within 24 h of delivery as pre-
viously described [5, 39]. Favourable ethical approval
was given by the National Research Ethics Service
(10/H10130/62). UC-MSCs were obtained by proces-
sing ~ 30 cm of whole UC, which was weighed and
minced into small pieces (~ 2 mm3) before digesting
with 1mg/ml collagenase I (> 125 digesting units/mg;
Sigma-Aldrich, Dorset, UK) for 1 h at 37 °C. Tissue was
removed from the digest, and the supernatant was centri-
fuged at 80g for 10min; the pellet was re-suspended in a
complete medium (as described for BM-MSCs) and plated
onto tissue culture plastic (Sarstedt, Leicester, UK). A
‘hybrid’ process was used for UC-MSC expansion in
the Quantum®, whereby UC-MSCs were expanded first
on TCP and after the first expansion (P0) 5 × 106 were
loaded into the Quantum® system for the second
expansion phase (P1). As for BM-MSCs, UC-MSCs
were grown in complete media on TCP and in the
Quantum®.
Light microscopy
Phase-contrast images of Quantum®-expanded cells
re-seeded onto TCP were taken using the Cell IQ Live
Cell Imagining Platform (CM Technologies, Tampere,
Finland).
The Quantum® cell expansion system
The Quantum® system was pre-coated with human cryo-
precipitate pooled from five donors (NHS Blood and
Transplant, Birmingham, UK) which was diluted 1:1
with PBS. As per the manufacturer’s instructions, to allow
for the attachment of the MSCs, the inner surface of the
fibres was coated overnight with 100 ml of human cryo-
precipitate solution before cell loading. The Quantum®
system provides a continuous perfusion of complete
medium, whilst simultaneously removing the equivalent vol-
ume of conditioned medium. Over the course of an expan-
sion in the Quantum®, the perfusion rate of fresh medium
was increased 16-fold to an inlet rate of 1 .6 ml/min, as
cell populations grew. Lactate concentration in the con-
ditioned medium was assessed daily using a Lactate
Plus meter (Nova Biomedical, Runcorn, UK); this measure
was used to inform on incremental increases in media
perfusion rate as a surrogate marker of cell number, as per
the manufacturer’s instructions.
Sub-population characterisation in BM-MSC cultures
Cells were harvested by trypsinisation from the Quantum®
bioreactor at P0, using 0.25% (v/v) Trypsin in ethylenedi-
aminetetraacetic acid (EDTA) for 8min and from sister
populations grown on TCP, using 0.05% (v/v) Trypsin in
EDTA for 5min. Cells were pelleted and re-suspended in
2% bovine serum albumin (BSA) in PBS. Cells were then
counted, and 20,000 cells were used for each antibody and
the control tube. Cells were stained with the following
antibodies, with the purpose of defining macrophage
sub-populations and their M1/M2 polarity [40–43]:
CD14-Peridinin-chlorophyll proteins-Cy5.5 (PerCP-Cy5.5)
(clone M5E2), CD80-Phycoerythrin (PE) (clone L307.4),
CD86-Fluorescein isothiocyanate (FITC) (clone FUN-1),
CD163-PerCPCy5.5 (clone GH1/61) and CD206-Brilliant
violet 421 (BV-421) (clone 19.2). Appropriate isotype-
matched IgG controls were used throughout. Cells were
analysed on a FACSCanto II flow cytometer using Diva 7
software (Becton Dickinson & company, Oxford, UK).
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Interleukin-8 (IL-8) in conditioned medium generated
from the Quantum® and TCP parallel cultures for freshly
isolated BM cultures was assessed using a Quantikine®
enzyme-linked immunosorbent assay (R&D Systems,
Bio-techne, Minneapolis, MN) according to the manufac-
turer’s instructions.
Calculation of growth kinetics
Doubling time (DT) was calculated using the formula
DT = (t2 − t1)ln (2)/ln (n2/n1) where n2 is the cell num-
ber at harvesting, n1 is the cell number at seeding, t2 is
the time at cell harvest and t1 is the time at seeding. It
should be noted that due to the inoculation procedure it
is estimated that 30% of the sample is lost in the inocu-
lation loop of the bioreactor at the time of cell seeding.
Flow cytometry immunoprofiling of MSCs
BM-MSCs and UC-MSCs were harvested by trypsinisa-
tion at P0 and P1, pelleted and 20,000 cells per tube
were re-suspended in 2% BSA for flow cytometry as de-
scribed previously. The following antibodies against
markers indicative of MSC profiles [6] were used:
CD90-PE (clone 5E10), CD105-Allophycocyanin (APC)
(clone 266), CD73-BV421 (clone AD2), CD19-BV421
(clone HIB19), CD34-APC (clone 581), CD45-PE (clone
HI30), HLA-DR-APC (clone TU36) and CD271-BV421
(clone C40-1457). Integrin profiles were also assessed
using antibodies against CD29-APC (clone MAR4),
CD49a-PE (clone SR84), CD49b-BV421 (clone 12F1),
CD49c-PE (clone C3 II.1) and CD51/61-PE (clone
23C6). Chondrogenic potency markers were assessed
using antibodies against CD166-BV421 (clone 3A6),
CD39-APC (clone TU66), CD44-PerCp-Cy5.5 (clone
G44-26) (all from Becton Dickinson & Company, Ox-
ford, UK), CD151-PE (clone 14A2.H1), receptor tyrosine
kinase-like orphan receptor 2 (ROR2)-APC (clone
231509) and fibroblastic growth factor receptor3
(FGFR3)-PE (clone 136334) (R&D systems, Abingdon,
UK). Immunomodulatory markers were assessed using
the following antibodies: CD40-PE (clone 5C3),
CD80-PE (clone L307.4), CD86-FITC (clone 2331),
CD106-APC (clone 51-10C9) and CD317-PE (clone
26F8). Appropriate isotype-matched IgG controls were
used throughout. Cells were analysed on a FACSCanto II
flow cytometer using Diva 7 software (Becton Dickinson
& company, Oxford, UK).
Stimulation of cells with IFN-γ
The pro-inflammatory cytokine IFN-γ (Promokine, Hei-
delberg, Germany) was used to stimulate cells at a con-
centration of 25 ng/ml [44]. Following expansion in the
Quantum® bioreactor, P1 cells were harvested and
seeded onto TCP (P2) and cultured for 24 h at 37 °C,
after which IFN-γ was added to their growth media for a
further 24 h. RNA was then extracted (as described
below), and the expression of several genes was assessed
via RT-qPCR.
Differentiation assays
BM-MSCs and UC-MSCs at P2 were assessed for their
osteogenic, adipogenic and chondrogenic differentiation
potential using published assays [45, 46]. Cells were
seeded at a density of 5 × 103/cm2 in 24-well plates
(Sarstedt, UK) and grown in monolayer in DMEM F12
and FCS (10%) until they reached ~ 90% confluency, at
which time, in test wells (in triplicate), complete medium
was replaced with either osteogenic and adipogenic
medium. Control wells for each condition were also main-
tained for 21 days with medium changes every 2–3 days.
Osteogenic differentiation medium contained: DMEM
F12, FCS (10%), β-glycerophosphate (10mM), dexametha-
sone (10 nM) and L-ascorbic-acid (50 μM). Adipogenic
differentiation medium contained DMEM F12 and FCS
(10%), insulin-transferrin-selenium-X (ITS) (1%) (Gibco,
UK), isobutylmethylxanthine (0.5 μM) (Sigma, UK), de-
xamethasone (1 μM) and indomethacin (100 μM). Os-
teogenic and adipogenic controls used media containing
DMEM F12, FCS (10%). For differentiation assessments at
21 days, cells were fixed with buffered formalin (10%) in
PBS for 10min at room temperature and stained with
naphthol-AS-BI phosphate and fast red for 1 h to assess
alkaline phosphatase activity for osteogenesis or oil red-O
for 1 h to assess lipid formation for adipogenesis.
A pellet culture system was used to assess chondrogenic
differentiation potential. Cells (2 × 105) were centrifuged
in a 1.5-ml Eppendorf (500g for 5min) in 1ml of chon-
drogenic medium consisting of DMEM-F12, FCS (2%),
gentamicin (10 μg/ml−1), ITS (1%), ascorbic acid (0.1
mM), dexamethasone (10 nM) and transforming growth
factor β1 (TGF-β1) (10 ng/ml−1) (Peprotech, UK). Pellet
cultures were maintained for 21 days, with media
changes every 2–3 days. Cell pellets were frozen in li-
quid nitrogen and stored at − 80 °C prior to use. Pellets
were sectioned (7 μM) on a cryostat (Bright Instrument
Co Ltd., Huntingdon, UK) onto poly-l-lysine-coated
slides and stained for glycosaminoglycans (GAGs) using
toluidine blue, a metachromatic stain.
Toluidine blue staining
Slides with adhered, sectioned pellets were removed
from − 20 °C storage and allowed to reach room
temperature. Pellets were then flooded with 1% aqueous
toluidine blue (BDH) stain solution for 30 s and rinsed
in tap water. Slides were left to air dry before mounting
under glass coverslips with Pertex mounting medium
(Cell Path Ltd).
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RNA isolation and reverse transcriptase-quantitative PCR
RNA was extracted from triplicate cultures of BM-MSC
and UC-MSC (P2) in a 24-well plate, with or without ex-
posure to IFN-γ for 24 h. RNA was extracted using the
RNeasy Mini kit (Qiagen, Sussex, UK), following the
manufacturer’s instructions. RNA was eluted from the
spin column with RNAse-free water and stored at − 80 °
C until needed. The following genes were assessed: indo-
leamine 2,3-dioxygenase (IDO), hepatocyte growth factor
(HGF), human leukocyte antigen G (HLAG) and prosta-
glandin E 2 (PGE2). RT-qPCR analysis was performed using
the SYBR green mastermix (Applied Biosystems, Warring-
ton, UK) with hypoxanthine phosphoribosyltransferase 1
(HPRT1) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as reference genes (Qiagen, QuantiTect
Primer Assay).
The reaction was measured in the QuantStudio 3
RT-qPCR system (Applied Biosystems) and Ct values
using the SDS software (Applied Biosystems). Following
normalisation to the reference genes HPRT1 and
GAPDH, the presence of genes of interest (mRNA) in
cells grown with IFN-γ stimulation was expressed as a
ratio compared to those grown in normal media without
IFN-γ. For stimulated cells, the gene expression profile
of IFN-γ-treated cells was expressed as a ratio compared
to un-stimulated cells, using the comparative threshold
method [47]. A twofold change threshold (up- or down-
regulated) was deemed biologically significant.
Measurement of telomere length
The telomere length for the fastest growing Quantum®
product, passage 1 UC-MSCs, was determined and com-
pared to those grown on TCP at the same passage. The
reason for assessing telomere length only in UC-MSCs
is because of their higher proliferation rate; hence,
UC-MSCs are more prone to telomere shortening. DNA
was extracted from UC-MSC, grown in the Quantum®
bioreactor and on TCP at P1, using the High Pure PCR
Template Preparation Kit (Roche, Sussex, UK). Extracted
DNA was stored at − 20 °C until needed. Telomere
length was determined using the TeloTAGGG kit
(Roche, UK) according to the manufacturer’s instruc-
tions, from UC-MSC (n = 4). One to two microgrammes
of genomic DNA from each sample population was
digested with a HinfI/RsaI mixture for 2 h at 37 °C and
then loaded onto a 0.8% agarose gel. The DNA frag-
ments were separated by gel electrophoresis for 2–4 h at
70 V and transferred to a nylon membrane (Macherey--
Nagel, Düren, Germany) by Southern blotting.
The blotted DNA fragments were hybridised to a digox-
igenin (DIG)-labelled probe specific for telomeric repeats
and incubated with a DIG-specific antibody covalently
coupled to alkaline phosphatase, which was visualised by
the chemiluminescence substrate CDP-Star. The telomere
bands were then visualised by exposing the blot to an im-
aging system (ChemiDoc™ Touch, Bio-Rad, UK) for 5 min.
The average terminal restriction fragment (TRF) length
was determined for each sample by comparing the signals
relative to the molecular weight standard.
Statistical analysis
Statistical analysis was performed using Prism version
6.0 software (GraphPad Software, La Jolla, CA, USA). A
Shapiro-Wilk test for normality was carried out for all
datasets, and data were analysed using either parametric
or non-parametric tests accordingly. Paired data were
analysed using a paired t test or a Wilcoxon-matched
pairs signed rank test. Data that were unpaired were
analysed using an unpaired t test or a Mann-Whitney
test. P values ≤ 0.05 were considered significant.
Results
Growth and cell morphology
BM-MSC cultures isolated and expanded from bone
marrow aspirate in the Quantum® and re-seeded onto
TCP for imaging showed the presence of typical
fibroblast-like MSCs with interspersed morphologic-
ally distinct round ‘fried egg’-shaped cells, described
by others as indicative of a macrophage or potentially
a progenitor sub-population (Fig. 1) [37]. These ‘fried
egg’ morphologies were absent in both ‘sister’ populations
cultured on TCP and in Quantum® or TCP populations
after a second expansion phase, which displayed homo-
geneous bipolar fibroblastic morphologies (Fig. 1a).
Quantum®- and TCP-expanded UC-MSCs at passage 2
showed similar uniform fibroblast-like morphologies
(Fig. 1a).
Bone marrow aspirate (20 ml) seeded directly into the
Quantum® generated cell yields of 23.1 ± 16.2 × 106 in
14 ± 2 days. In contrast, UCs yielded 6.9 ± 2.6 × 106
UC-MSCs per cord in 17 ± 4 days on TCP (Table 1). At
the end of the second expansion, the Quantum® gener-
ated a mean cell harvest of 131 ± 84 × 106 BM-MSCs
and 168 ± 52 × 106 UC-MSCs. The mean culture time
to achieve these numbers for BM-MSCs was 13 ± 1 days
and for UC-MSCs was 8 ± 2 days (Fig. 2). Hence,
UC-MSC yields were larger and grew significantly faster
in the Quantum® bioreactor compared to BM-MSCs
(*p = 0.029) (Fig. 1b, c).
BM-MSC sub-population characterisation
Bone marrow cultures isolated and grown in the Quantum®
(P0) were significantly more immunopositive for CD45
compared to sister populations on TCP (*p = 0.032)
(Fig. 3a). In co-expression analyses, we have shown that
those cells that displayed positivity for CD14 were also
immunopositive for CD80/86 and CD163/206 to varying
levels (Fig. 3b). Interleukin-8 secretion into the conditioned
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media was only detectable in bone marrow cultures iso-
lated and cultured in the Quantum® at P0 and was not
detected in the P1 BM-MSC expansion in the bio-
reactor; this data is included as supplementary material
(Additional file 2).
Immunoprofiling
In bone marrow cultures at P0, the cell adhesion
markers CD166 (activated leukocyte cell adhesion mol-
ecule) and CD49a (α1 integrin) were both significantly
lower on Quantum®-derived cells compared to TCP cul-
tures (*p = 0.024 and **p = 0.002, respectively) (Fig. 3a,
c). BM-MSCs grown in the Quantum® and on TCP at
passage 0 showed similar immunopositivity for all of the
other cell surface markers tested, which are indicative of
MSCs, chondrogenic potency and immunomodulatory
capacity (Fig. 3a, b).
At passage 1, no significant differences were observed in
marker immunopositivity, when comparing the two con-
ditions or cell types with the exception of two markers,
CD271 and CD34. Quantum®-grown BM-MSCs were
significantly more immunopositive for CD271 com-
pared to UC-MSCs (14.6 ± 2.6% and 2.8 ± 0.6% res-
pectively, *p = 0.029) and TCP BM-MSCs were more
positive for CD34 compared to UC-MSCs (5.9 ± 0.8%
and 3.1 ± 0.6% respectively, *p = 0.029) (Fig. 4a, b).
A
B C
Fig. 1 Cell morphologies and growth kinetics of BM- and UC-MSCs expanded in the Quantum® bioreactor and on tissue culture plastic (TCP). a
Phase-contrast images of BM-MSCs isolated in the Quantum® and re-seeded on TCP at P1 and BM-MSCs and UC-MSCs after P1 expansion in the
Quantum®, re-seeded on TCP at P2 (top rows), in comparison to TCP cultures at the same passage (bottom rows) . White arrows indicate
macrophage-like cells. Scale bars represent 100 μm. b Growth kinetics for BM-MSCs and UC-MSCs grown in the Quantum® at P1. Comparison of
MSCs generated from BM (grey line) or UC (black line) in the Quantum at P1 are displayed for comparison. c The P1 doubling time of BM-MSCs
was significantly longer than UC-MSCs grown in the Quantum®. Mann-Whitney U test (*p = 0.029). Mean values are plotted ± standard deviations
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IFN-γ stimulation of BM-MSCs and UC-MSCs grown
in both conditions did not induce the production of
co-stimulatory molecules (CD40, CD80 or CD86)
(Fig. 4c, d). HLA-DR was detectable at high levels only
in two BM-MSC donors grown on TCP (donor 1 and
donor 4, which showed levels of 53.7% and 42.3% on
TCP compared to levels of 0.5% and 0.1%, respectively,
in the Quantum®) and one UC-MSC donor (donor 2
when grown in the Quantum® showed 52.1% immuno-
positivity for HLA-DR compared to 0.4% on TCP)
(Fig. 4c, d). However, un-stimulated BM and UC popula-
tions did not produce HLA-DR. The immunomodulatory
markers CD106 and CD317 were also both produced to a
higher level on both cell populations following IFN-γ
stimulation compared to cells without stimulation;
however, there was no significant difference in produ-
ction between cells grown in the Quantum® or on TCP
(Fig. 4c, d).
Tri-lineage differentiation
The definitive demonstration of multipotency for a cell
is the ability to differentiate towards more than one cell
type. BM-MSCs and UC-MSCs cultured in the
Quantum® at passage 1 and induced at passage 2 showed
the potential to differentiate as shown by positive osteo-
genic, adipogenic and chondrogenic staining (Fig. 5).
Adipogenesis was seen with positive Oil red-O staining,
and osteogenic differentiation was demonstrated with
alkaline phosphatase staining. In addition, metachrom-
atic toluidine blue-stained chondrogenic pellets indi-
cated the presence of GAGs within the pellet matrices.
Some differences were seen between BM-MSCs and
UC-MSCs in terms of alkaline phosphatase staining
(indicative of osteogenesis), with BM-MSCs showing
stronger staining (Fig. 5), comparable to the previous
work in our group comparing these MSC sources when
grown on TCP [5]. Adipogenic staining of lipids was also
more evident in BM-MSC cultures whereas chondro-
genic staining of GAGs was comparable between both
cell types cultured in the Quantum® (Fig. 5).
Immunomodulatory gene expression
Quantum®-derived BM-MSC and UC-MSC cultures at
passage 1 showed a consistent and significant upregula-
tion of IDO in response to IFN-γ stimulation in all cul-
tures (Fig. 6). However, the relative fold change observed
for IDO in UC-MSCs was much higher than that
observed for BM-MSCs. BM3 showed the lowest expres-
sion of IDO with a relative fold change of 49, whereas
BM 1 showed the highest relative fold change of 984. In
Table 1 Passage 0 and passage 1 cell growth characteristics of
BM- and UC-derived cells in the Quantum® and on TCP
Donor 1 2 3 4
Passage 0
BM Quantum® MNC count (× 106/ml) 30.1 29.9 18.7 21.2
Cell harvest (× 106) 24.6 66.6 13.7 27.3
Days in culture 13 13 16 15
UC TCP Tissue digested (g) 27 25 30 36
Cell harvest (× 106) 6.1 5.1 5.5 10.7
Days in culture 20 20 17 12
Passage 1
BM Quantum® Cells seeded (× 106) 10 10 5 10
Cells harvested (× 106) 311.4 252.3 36 150
Days in culture 12 12 13 15
Doubling time (days) 1.6 1.6 3.0 2.3
UC Quantum® Cells seeded (× 106) 5 4.8 5 5
Cells harvested (× 106) 285.7 268.6 128.6 277.1
Days in culture 6 11 7 7
Doubling time (days) 0.8 1.5 1.1 0.9
A B
Fig. 2 Individual donor BM- and UC-MSC yields at passages 0 and 1. a Cell yields from BM-MSC after the first Quantum® harvest (P0) and UC-MSC
after harvest from TCP (P0). b Cell yields from BM-MSC and UC-MSC after the expansion in the Quantum® at P1
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contrast, the lowest relative fold change for UCs was
UC2 at 25529, with UC3 showing the greatest relative
fold change at 847589 (Fig. 6). Variable results for the
expression of HGF, HLA-G and PGE2 were observed
across BM- and UC-MSC populations.
Analysis of telomere length
The rapid expansion of UC-MSCs in the Quantum® did
not shorten the telomeres of UC-MSCs compared to
those grown on TCP. In fact, UC-MSC 1 and 2 showed
slightly longer telomeres when grown in the Quantum®
(UC1 9.9 kbp, UC2 8.6 kbp) compared to the same
population grown on TCP (UC1 9.8 kbp, UC2 8.3 kbp).
UC-MSC 3 and 4 had identical telomere lengths for both
culture conditions (Fig. 7).
Discussion
A strong case exists for the need to develop more cost-
effective cell-based therapies. Allogeneic cell expansion
using the Quantum® bioreactor clearly has the potential
to reduce the cost of producing therapeutic cells ex vivo.
Many laboratories have demonstrated the utility of the
system for the GMP manufacture of large quantities of
MSCs derived from the bone marrow, adipose tissues
[26–36] and even neural sources [48]. Quantum® GMP
manufacturing protocols have developed from early
studies which employed the use of research grade FCS
[26, 31], to more recent studies that have switched to
pooled human platelet lysate for the supplementation of
Quantum® cultures [28, 35, 36]. Similarly, a shift in the
preferred choice of substrate utilised to coat the polysul-
phone hollow fibres inside the bioreactor has been ob-
served, moving from a recombinant fibronectin source
to a cryoprecipitate blood product, as a clinical grade
source of fibronectin [28, 32, 34]. The innovation de-
scribed in the current study is the use of the Quantum®
system for the expansion of umbilical cord-derived
MSCs (UC-MSCs) and the development of a ‘hybrid’
manufacturing protocol for UC-MSC expansion using
the Quantum® system. To our knowledge, this has not
been demonstrated before in the Quantum® bioreactor.
Additionally, we have undertaken a comprehensive
A
B C
Fig. 3 a–c Characterisation using flow cytometry on Quantum®- and TCP-expanded BM-MSCs at P0. CD45 immunopositivity was significantly
greater on cells grown in the Quantum®, but CD166 and CD49a immunopositivity was significantly lower. Paired t tests (*p = 0.033, *p = 0.024 and
**p = 0.002, respectively). Mean values are plotted ± standard deviations
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phenotypic evaluation of our UC-MSC Quantum® prod-
uct in terms of ISCT criteria for MSCs, in comparison to
sister populations expanded using traditional TCP tech-
niques and BM-MSCs cultured in both ways. A bank of
characterisation tests was utilised to study the phenotype
further, including a panel of markers indicative of chon-
drogenic potency and immunomodulatory capacity. In
addition, and unlike all other studies using the Quantum®
system, we have characterised our UC-MSC Quantum®
versus TCP products in terms of telomere length, an
important marker linked to cellular ageing [49].
We report that the number of BM- and UC-MSCs
generated using the Quantum® system is higher than
those expanded using TCP protocols, thus demon-
strating an improved potential for the banking of mul-
tiple doses of MSCs from both tissue sources for
allogeneic treatment. For the first time, we have dem-
onstrated that there are no discernible differences be-
tween UC-MSCs grown using up-scale manufacturing
techniques or TCP methodologies. Importantly, we have
characterised UC-MSCs grown using each methodology
in terms of accepted criteria for MSC, which test their
response to a pro-inflammatory stimulus, a proposed po-
tential therapeutic mode of action for this cell type. The
propagation of large cell doses has important clinical
implications for their use in treating indications that
might require high cell numbers or for repeat doses.
Moreover, it has been suggested that higher cell doses
may be required when administering cellular therapies
via a systemic route, e.g. intravenous deliveries, com-
pared to a direct application into injured/diseased tis-
sues [50, 51]. Our live cell imaging and flow cytometry
data indicated that Quantum®-expanded BM-MSCs and
UC-MSCs at passage 1 adhere to the ISCT definition of
MSCs and had comparable chondrogenic potency and
immunomodulatory immunoprofiles before and after
pro-inflammatory stimulation with IFN-γ. This indi-
cates that BM- and UC-MSC populations have retained
A C
B D
Fig. 4 Characterisation using flow cytometry on Quantum®- and TCP-expanded BM-MSCs and UC-MSCs at P1. No significant differences in
immunoprofile were noted between culture conditions; however, BM-MSCs (a) expressed significantly more CD271 and CD34 compared to UC-
MSCs (b) after P1 expansion in the Quantum® (p = 0.029). Cell surface marker immunopositivity following IFN-ϒ stimulation on P1 Quantum®- and
TCP-expanded c BM-MSC and d UC-MSC re-seeded onto TCP at P2 was comparable for the co-stimulatory markers CD40, CD80 and CD86. Some
BM-MSCs grown on TCP and UC-MSCs grown in the Quantum® at P1 and stimulated with IFN-γ at P2 were immunopositive for HLA-DR. All of
the cultures tested upregulated CD106 and CD317 in response to IFN-γ, with no significant difference between the Quantum®- and TCP-
expanded cells. Mean values are plotted ± standard deviations
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immunomodulatory phenotypic properties indicative of
MSCs [9] following rapid culture expansion in the
Quantum® bioreactor. Some donor-donor variability
was observed and has been reported previously [39],
particularly in terms of HLA-DR upregulation, which
highlights the need to screen individual donors rigor-
ously prior to banking for allogeneic use. What we do
not yet fully understand are which markers are of
importance in terms of potency for cell banking and
for which indication, much more work is required to
establish such release and banking criteria for clinical
MSC products.
Some notable differences in the characteristics of
MSCs expanded using the bioreactor compared to TCP
are reported in this study. For example, at P0, BM-MSCs
grown in the Quantum® showed lower immunopositivity
for all of the cell adhesion molecules tested and signifi-
cantly for CD49a or the integrin α1 subunit. This indi-
cates that there is a differential regulation of adhesion
molecules in response to the differing surface chemis-
tries presented and it appears that polystyrene alone cf.
polysulfone coated with cryoprecipitate (rich in fibronec-
tin) induces this alteration. Similarly, another study noted
the upregulation of CD49a in rat MSCs in response to
polystyrene and not on other titanium-coated surfaces
[52]. It remains to be seen whether the up/downregulation
of adhesion molecules is a beneficial response in terms of
the clinical efficacy of these cell populations, but it is likely
that some of these molecules are important for the proli-
feration, attachment and migration of cells through target
tissues and matrices [53–55]. In addition, CD49a has
been suggested to play an essential role in the regula-
tion of MSC proliferation and cartilage production [56].
Tri-lineage differentiation data demonstrated that whilst
UC-MSCs demonstrated comparable chondrogenic and
adipogenic differentiation capacity, they showed less alka-
line phosphatase staining indicative of poorer osteogen-
esis. This is not a feature unique to Quantum®-expanded
products and is comparable to previously published work
in our group where BM-MSCs and UC-MSCs were grown
on TCP [5]. However, we acknowledge that alkaline phos-
phatase staining alone is insufficient to fully determine
osteogenic potential and protein assays for typical markers
of osteogenesis should be used to further evaluate dif-
ferentiation status. Whilst these cells have all shown
capability to undergo tri-lineage differentiation, the
mode of action of MSCs in cartilage repair is still
unclear. Rather than MSCs differentiating in vivo to form
repair tissues, there is evidence from in vitro and in vivo
studies that MSCs exert trophic effects on endogenous
Fig. 5 Tri-lineage assessment of the Quantum®-expanded BM- and UC-MSCs. Representative images of osteogenic, adipogenic and chondrogenic
differentiation of BM-MSCs (top row) and UC-MSCs (bottom row) grown in the Quantum® bioreactor at P1 and differentiated at P2 for 21 days.
BM-MSCs displayed more alkaline phosphatase activity (osteogenesis indicator) and the presence of more lipids (indicative of adipogenesis)
compared to UC-MSCs, whereas chondrogenic GAG assessments were comparable across cell types. Scale bars represent 100 μm
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cells and secrete immunomodulatory molecules that
dampen inflammatory processes contributing to disease
progression [8–10].
Our analyses of immunomodulatory genes following
IFN-γ stimulation showed variable results between do-
nors, but IDO was consistently upregulated by both BM-
and UC-MSCs. The response reported for UC-MSCs was
much higher (20–800k relative fold change) compared to
BM-MSCs, which expressed a more modest response
(50–1000 relative fold change). IDO is a potent immuno-
modulatory molecule which depletes tryptophan, causing
the suppression of T cells [57]. Our group and others have
previously demonstrated that TCP-expanded BM- and
UC-MSC populations upregulate the IDO gene in
response to pro-inflammatory stimulation in vitro, but to
varying degrees from different individuals [11, 39]. The
reason for the higher expression levels of IDO in
UC-MSCs is most likely associated with foetal-maternal
tolerance during pregnancy as IDO has an important
role to play in protecting the foetus from the maternal
immune system [58]. Another study investigating only
BM-MSCs reported similar variable upregulation of
IDO and suggested that the reason for this was the
existence of an intrinsic variation in responsiveness and
plasticity of MSC to inflammatory cytokines [11]. This
provides additional evidence for the importance of rigor-
ous allogeneic cell bank characterisation and in particular
for their immunomodulatory potential tested prior to
banking, in order to assure their immunomodulatory
function. This is especially important if immunomodu-
lation is the main mechanism of therapeutic action or if
cells are being transplanted into inflamed tissues.
Shortened telomeres are known to play an important
role in the cellular ageing process [49]. In previous studies,
MSCs derived from both bone marrow and umbilical cord
tissues have shown that their telomeres shorten progres-
sively during successive cell divisions after ex vivo expan-
sion, down to a threshold length at which time replicative
senescence is observed [39, 49]. However, in the current
study, no differences in telomere length in Quantum®- and
TCP-expanded UC-MSCs (the fastest growing cell popu-
lation included in the study) were found, which showed
A B
Fig. 6 RT-qPCR analyses for the expression of immunomodulatory genes in Quantum®-expanded BM- and UC-MSCs. a BM-MSCs and b UC-MSCs
cultured in the Quantum® bioreactor at passage 2 following stimulation with 25 ng/ml IFN-γ for 24 h. Only IDO was consistently and significantly
upregulated in response to IFN-γ stimulation in both cell types. Gene expression was normalised to GAPDH and HPRT1. Gene expression for IFN-
γ-stimulated cells is expressed relative to those grown in normal media without the inflammatory stimulus. Stars indicate genes which are
significantly up- or downregulated. Mean values are plotted ± standard deviations
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that their rapid expansion rate in the bioreactor had not
decreased their longevity compared to the same popula-
tions grown more slowly on TCP.
Other studies have reported the presence of a sub-
population of progenitor cells in Quantum® cultures
harvested after bone marrow aspirates were added dir-
ectly to the bioreactor [59]. The reasons for this
sub-population persisting only in Quantum® bone mar-
row isolations are unclear, but could be related to the
lack of bone marrow density gradient centrifugation
prior to seeding, or the cryoprecipitate coating of the
bioreactor. The mechanism of isolation and the distinct
phenotype described for this sub-population warrants
further study. We observed a sub-population with a
‘fried egg’-like morphology in primary bone marrow
cultures from the bioreactor. Our morphological as-
sessments and the fact that these bone marrow cultures
isolated and grown in the Quantum® (passage 0) were
significantly more immunopositive for CD45 compared
to sister populations on TCP led us to hypothesise that
they could represent a macrophage sub-population. We
investigated this further, and our co-expression analyses
showed that these cells expressed CD14 and were also
immunopositive for CD80/86 and CD163/206, indi-
cative of M1 and M2 macrophage polarisation, respec-
tively [60, 61]. Our hypothesis that these cells displayed
Fig. 7 The telomere length of UC-MSCs grown in the Quantum® bioreactor and on tissue culture plastic (TCP) at passage 1. The telomeres of UC-
MSC cultures expanded in the Quantum® were the same or greater molecular weight (when assessed via electrophoresis) compared to sister
populations expanded on TCP
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macrophage-like characteristics was corroborated fur-
ther by our secretome analysis which only found IL-8
detectable in cultures with this sub-population and not
in comparable cultures where this sub-population was
absent (in sister populations grown on TCP and follo-
wing a second round of expansion in the Quantum®).
These macrophage-like cells could also have therapeutic
applications, especially M2 polarised sub-populations,
shown to be present by immunopositivity for CD163/206
and known to possess desirable functions in tissue repair
processes [62, 63]. However, we also noted that these
macrophage-like cells were lost after a second round of
expansion; hence, the Quantum® and TCP techniques
produced comparably ‘pure’ MSC populations at the
end of P1, which could be important for defining
allogeneic cell products and for potential regulatory
release criteria.
Conclusions
When taken together, our results suggest that the semi-
automated Quantum® system can be used to rapidly
expand large numbers of MSCs from bone marrow and
umbilical cord tissues. The Quantum® manufacturing
process is less labour-intensive and involves fewer ‘open’
procedures compared to expansion in flasks and as such
is likely to be more cost effective, safe and reproducible.
The development of an off-the-shelf up-scale manufac-
tured allogeneic cell product could provide great benefit
to patients who may not respond to current treatments,
for example if their own cells do not grow or do not
possess the correct therapeutic phenotype. Further, allo-
geneic products do not require a harvest procedure and as
such the patient will require only one and not two surgical
interventions to receive the treatment. In addition, the
manufacturing costs of an allogeneic product are likely to
be significantly lower and require less time and effort
when using the Quantum® compared to traditional TCP
expansion techniques [64].
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